

CYP2C19: mirtazapine

3506 to 3508

IM = intermediate metaboliser (*1/*2, *1/*3, *17/*2, *17/*3) (reduced CYP2C19 enzyme activity), NM = normal metaboliser (*1/*1, *1/*17) (normal CYP2C19 enzyme activity), PM = poor metaboliser (*2/*2, *2/*3, *3/*3) (absent CYP-2C19 enzyme activity), UM = ultrarapid metaboliser (*17/*17) (elevated CYP2C19 enzyme activity).

Brief summary and justification of choices:

Mirtazapine is converted by CYP2D6 and CYP1A2 to inactive hydroxy metabolites. Mirtazapine is also converted by CYP3A4 to the pharmacologically active N-demethyl metabolite and inactive N-oxide metabolites.

None of the available publications (a study with 171 patients with the number of intermediate, poor, and ultrarapid metabolisers not mentioned (Scherf-Clavel 2022), a study with 49 patients among whom 10 intermediate metabolisers (Grasmäder 2004), and a case report with 1 poor metaboliser (Johnson 2006)) found an effect of the CYP2C19 phenotype on metabolism, adverse effects or effectiveness of mirtazapine. The KNMP Pharmacogenetics Working Group concluded that there is no evidence for a gene-drug interaction (no/no-interactions).

You can find an overview of the observed kinetic and clinical effects per phenotype in the background information text of the gene-drug interactions in the KNMP Kennisbank. You might also have access to this background information text via your pharmacy or physician electronic decision support system.

Source	Code	Effect	Comments
ref. 1	3	171 patients from two cohorts (107 and 64 patients from each of the	Authors' conclu-
Scherf-Clavel		cohorts) were treated with mirtazapine (final dose 7.5-120 mg/day	sion:
M et al.		(mean 45 mg/day)).	'Dose-corrected
Effects of phar-		The cohort from which 107 patients were derived included patients	concentrations of
macokinetic		with unipolar depression. Therapeutic drug monitoring was performed	quetiapine and
gene variation		according to the doctor's choice and not per protocol and used to	mirtazapine were
on therapeutic		adjust the dose. Patients were analysed after 6 weeks of treatment.	not associated
drug levels and		The other cohort included patients with at least a moderate depressive	with the exa-
anti-depressant		period (Hamilton Depression Rating Scale-21 (HAMD ₂₁) > 14). Thera-	mined dipiolypes/
treatment		peutic drug monitoring was performed in week 3, 5, and 7 of treatment	Pk gene variation
response.		and used to adjust the dose. Patients were analysed after 7 weeks of	did not affect
Pharmacopsy-		treatment.	treatment res-
chiatry		49% of patients were responders (31% in the cohort from which the	ponse.'
2022 Jul 15.		107 patients were derived and 77% in the other cohort). Treatment	P
Online ahead of		response was defined as \geq 50% reduction in HAMD ₂₁ -score. 31% of	
print.		patients showed remission (19% in the cohort from which the 107	
PMID:		patients were derived and 52% in the other cohort).	
35839823.		Change of antidepressant due to adverse drug reactions was asses-	
		sed in the cohort from which 107 patients were derived (not observed,	
		but data missing in 64% of patients). Adverse drug reactions were	
		assessed in the other cohort (1 mild and 1 medium adverse drug reac-	
		tion were observed),	
		Clinical improvement was measured as the percentual reduction in the	
		HAMD ₂₁ -score. Remission was defined as a HAMD ₂₁ -score \leq 7.	
		Trough serum concentrations in steady state were determined.	
		Dimensional outliers (≥ 4 SD from the mean) from the (dose-correc-	
		ted) serum concentration were set as missing data.	
		Comedication with CYP2C19 inhibitors was excluded, but smoking	
		was not. 34% of the patients was smoker. Results were not corrected	
		for smoking status. The authors do not indicate whether the difference	

The table below uses the KNMP nomenclature for NM, PM, IM and UM. As a result, the definitions of NM, PM, IM and UM in the table below can differ from the definitions used by the authors in the article.

ation do not correct for the cohort from which the patient was derived. Authors Patients with conferonic-corrected for the total number of genes (7) and the total number of gravity (1/11) and the total number of gravity (1/11) and the total number of total total number of total number of total total total number of total number of total total number of total total number of total number	ref. 1, continu-		in response and remission betw	veen the two cohorts is significant and			
P-values were Bonferoni-corrected for the total number of drugs (4) investigated. As a result p ≤ 0.001 and the total number of drugs (4) investigated. As a result p ≤ 0.001 was considered significant. Genotyping: The number of NM (*1/*1 and *1/*17), IM, PM and UM is not mentioned. The number of NM (*1/*1 and *1/*17), IM, PM and UM is not mentioned. PM: AA Mr: AA UM: AA Results: Results for PM versus IM versus *1/*17 versus *1/*17 versus UM: (percentual reduction in (percentual reduction in (there was a trend for an associa- tion before Bonferroni-correction (p = 0.059, NS)) Authors' conclu- tion before Bonferroni-correction (p = 0.059, NS). Mot: Genotyping was for *2 and *17. These are the most important gene variants in this German population. Authors' conclu- tion of mitazapine NS toor: The patients seemed to res- poor metabo- lizer for cyto- chromes P450 A 50-year-old woman who previously had to discontinue veniafaxine, and treated with mitrazapine. Mitazapine 45 mg/day without sedation occurring. Authors' conclu- semed to res- poor metabo- lizer for cyto- chromes P450 CNS Spectr 2006;11:757- 60. 3 65 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with mitrazapine. Mitrazapine diarnance of trough concentrations measured on a weekly basis after attaining steady state. 20% of the treated with mitrazapine. Mitrazapine diearance of metabolism." Authors' conclu- sor: The clearance of the clearance of metabolism." Poultistion a case report a clinearia of the relevance of nuitazapine diation of the C/*P2C19 substates and 4% C/*P2C19 substates and 4% C/*P2C19 inten- mediation of the C/*P2C19 geno- treated with sub- med	ation		do not correct for the cohort from which the patient was derived.				
and the total number of drugs (4) investigated. As a result p \$ 0.001 was considered significant. Genotyping: The number of NN (*1/*1 and *1/*17), IM, PM and UM is not mentioned. Results: Results in PM versus IM versus *1/*1 versus *1/*17 versus UM: clinical improvement inhAMD ₂ : score) INS PM: AA M:: AA M.: AA Model in the fore Bonferoni-correction (p = 0.059, NS). Model inhamonic			P-values were Bonferroni-corre				
was buildened symination. Genotyping: The number of NM (*1/*1 and *1/*17), IM, PM and UM is not mentioned. Results: Percentual reduction in HAMD ₂₁ score) Not: Consorted concentra- UM: AA W: AA % of patients with remission NS dose-corrected concentra- tion of mitrazapine al. Note: Genotyping was for *2 and *17. These are the most important gene variants in this German population. ref. 2 Johnson M et al. A poor metabo- lizer for cyto- chromes P450 2D6 and 2C19: a case report a case report a case report on antidepres- sant treatment. CNS Spectr 2006;11:757- 60. 3 Gestattment: CII Pharmackine- tic analysis of mitrazapine. Eur J Clin Phar- macol 2004;60:473- 80. 65 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with mitrazapine. Eur J Clin Phar- macol 2004;60:473- 80. 4. 65 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with mitrazapine. Mitrazapine elevance of the effect on mitrazapine. Eur J Clin Phar- macol 2004;60:473- 80. 4. 6. IM: AA 6. Fatients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with mitrazapine. Mitrazapine clearance di not improve the prediction of mitrazapine. Eur J Clin Phar- macol 2004;60:473- 4. Authors' conclu- sion: The clearance of mediation (16k CYP2C19 genotype to a population pharmacokinetic mediation (16k CYP2C19 genotype to a population pharmacokinetic model for mitrazapine clearance di not improve the prediction of mitrazapine. NOTE: only the predominant null allele *2 was genotyped. Authors' conclu- sion the c			and the total number of drugs (
Genotyping: The number of NM (*1/*1 and *1/*17), IM, PM and UM is not mentioned. Results: Results: Results: Results: Image: Comparison of the term of the term of the term of the term of te			was considered significant.				
PM: AA Results: Results: Results: Results: Results: Quercentul reduction in HAMD2: score) (There was a trend for an association before molecorrection (p = 0.059, NS)) M: AA 0 M: AA 0 M: Construction of mitrazapine NS Johnson Mt 1 A. 50-year-old woman who previously had to discontinue ventafaxine, and to be CYP2C19 *2/*2 and CYP2D6 *4/*4. She was started on scheroni-correction association occurring. Authors' conclusion: "The patient scheroni-correction (p = 0.059, NS)) YDM: AA A 50-year-old woman who previously had to discontinue ventafaxine, and to be CYP2C19 *2/*2 and CYP2D6 *4/*4. She was started on funitazapine 45 mg/day without sedation occurring. Authors' conclusion: "The patient scheroni-correction (p = 0.059, NS)) YDM: AA 65 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with mitrazapine. Mitrazapine trough concentrations were measured on a weekly basis after attaining steady state. 20% of the investigate the relevance of the effect on mitrazapine clearance. Authors' conclusion: "The clearance of CYP2D6 intermediate metabories investigate the relevance of the effect on mitrazapine clearance. Reduct on the relevance of the effect on mitrazapine clearance. Authors' conclusion: No delife mitrazapine clearance di not improve the prediction of mitrazapine. YDM: AA Bo patients with co-medication was to so mall to corearapine. Addition o			Genotyping:				
mentioned. Results: Results: Results for PM versus IM versus *1/*1 versus *1/*17 versus UM: clinical improvement (percentual reduction in HAMD2; score) NS (There was a trend for an associa- tion before Bonferroni-correction (p = 0.059, NS)) ref. 2 1 A 50-year-old woman who previously had to discontinue venifatione, antitriptyline and escitalopram moncharpies due to side effects was furtilizer for cybo. Authors' conclu- sizer for cybo. 206 and 2C19: a case report on antidepres- sant treatment. CNS Spectr PM: AA 65 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were measured on a weeky basis after attaining steady state 20% of the trough concentrations measured were found in users or fleevant oc- medication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients with co-medication was to small to investigate in certaine. Authors' conclu- sion: *10 certained and the CYP2C19 genotypeed (39x *1/*1, 10x *1/*2), were frazamine. Authors' conclu- sion: *10 certained and the minitazapine. 206 of 0.0-077- 80. 3 65 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were measured on a weeky basis after attaining steady state 20% of the trough concentrations measure were found in users or fleevant oc- medication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients with oc-medication was to so small to investigate the relevance of the effect on mitrazapine. Addition of the CYP2C19 genotype to a population pharmackinetic male relevance of the effect on mitrazapine clearance of the clearance mited- elearance mited- elearance mited-			The number of NM (*1/*1 and *	1/*17), IM, PM and UM is not			
Results: Results: Results: Results: Not: Inical improvement (percentual reduction in HAMD ₂₁ score) NS Inical improvement (percentual reduction in HAMD ₂₁ score) NS 1 More Genotyping was for *2 and *17. These are the most important gene variants in this German population. Authors' conclu- sion of mitrazapine Authors' conclu- sion of mitrazapine rof a 0.360, NS) Note: Genotyping was for *2 and *17. These are the most important gene variants in this German population. Authors' conclu- sion on to be CYP2C19 *2/*2 and CYP2D6 *4/*4. She was started on mitrazapine 45 mg/day without sedation occurring. Authors' conclu- sion: "The patient taces report 7ef. 3 OS patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were measured on a weekly basis after attaining steak state. 20% of the investigate the relevance of the effect on matox was to small to investigate the relevance of the effect on mitrazapine clearance. A multiple linear regression analysis did not identify the CYP2C19 inhibitors). Authors' conclu- sion: "The clearance of The number of patients, with co-medication was too small to investigate the relevance of the effect on mitrazapine clearance. A multiple inter regression analysis did not identify the CYP2C19 genotype as a possible relevant factor in the clearance of mitrazapine Addition of the CYP2C19 genotype to a population pharmacokinetic investigate the relevance of the effect on mitrazapine. A multiple inter regression analysis did not identify the CYP2C19 genotype as a possible relevant factor in the clearance of mitrazapine. Eur J CIn Phar- macol Bo. <			mentioned.				
PM: AA Results for PM versus IM versus *1/*17 versus UM: clinical improvement (percentual reduction in HAMD21 score) NS (There was a trend for an associa- tion before Bonferroni-correction (p = 0.059, NS)) PM: AA M: AA UM: AA % of patients with remission dose-corrected concentra- tion of mitazapine NS (There was a trend for an associa- tion before Bonferroni-correction (p = 0.059, NS)) ref. 2 Johnson M et al. 1 A 50-year-old woman who previously had to discontinue veniafaxine, amitriptime and escitalopram monotherapies due to side effects was found to be CVP2C19 '272 and CVP2D6 '474. She was started on mitrazapine 45 mg/day without sedation occurring. Authors' conclu- sion: "The patient seemed to res- pond well to mit- tazapine, a drug that does not depend exten- sion mitrazapine. 206 and 2C19: a case report on antidepres- sant treatment. Con Spectr 2006;11:767- 60. 3 65 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with mitrazapine. Mitrazapine trough concentrations were substrates and 4% CYP2C19 inhibitors). The number of patients with co-medication was too small to investigate the relevance of the effect on mitrazapine clearance of medication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients, with co-medication was too small to investigate the relevance of the effect on mitrazapine clearance of medicate metabo- liace No other addition of the CYP2C19 genotype to a porolyption pharmacokinetic model for mitrazapine clearance did not improve the prediction of plasma concentrations. Authors' conclu- sion: The clearance of the clearance of mitrazapine dearance did not improve the prediction of plasma concentrations. Authors' conclu- sion: The following covariates were enclu			Deputto :				
ref. 2 1 Authors' conclusion of the top and solution of the top and top a			Results for PM versus IM vers	us *1/*1 versus *1/*17 versus LIM:			
PM: AA IM: AA UM: AA UM: AA UM: AA UM: AA Ipercentual reduction in HAMD ₂₁ score) There was a trend for an associa- tion before Bonferroni-correction (p = 0.059, NS)) % of patients with remission dose-corrected concentra- tion of mitrazapine NS Note: Genotyping was for "2 and "17. These are the most important gene variants in this German population. Authors' conclu- sion: "The patients" found to be CYP2C19 "2/"2 and CYP2D6 "4/"4. She was started on mitrazapine 45 mg/day without sedation occurring. Authors' conclu- sion: "The patient seemed to res- pond well to mi- tazapine, a drug that does not depend exten- son antidepres- sant treatment. CNS Spect 2006;11:757- 60. Authors' conclu- sion: "The patient seemed to res- pond well to mi- tazapine. Mitrazapine trough concentrations were measured on a weekly basis after attaining steady state. 20% of the trough concentrations measured were found in users of relevant to medication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients with co-medication was to small to investigate the relevance of the effect on mitrazapine clearance. A multiple linear regression analysis did not identify the CYP2C19 inhibitors. The number of patients with co-medication was to small to investigate the relevance of the effect on mitrazapine clearance. A multiple linear regression analysis did not identify the CYP2C19 inhibitors. NOTE: only the predominant null allele "2 was genotyped. Authors' conclu- sion: "The following covariates were included in the clearance mixed- effects specifica- tion to model interindividual variability: CYP2C19 geno- type and co-me- tredication with sub-			clinical improvement	NS			
PM: AA M: AA UM: AA UM: AA UM: AA HAMD ₂₁ score) (There was a trend for an associa- tion before Bonferroni-correction (p = 0.059, NS)) % of patients with remission NS // M: AA // M: AA um: AA UM: AA // M: AA ref. 2 Johnson M et al. A 50-year-old woman who previously had to discontinue veniafaxine, amitriptyline and escitalopram monotherapies due to side effects was found to be CYP2C19 *21 and CYP2De 4/14. She was started on mitrazapine 45 mg/day without sedation occurring. Authors' conclu- sion: PM: AA a case report on antidepres- sant treatment. 9 A 50-year-old woman who previously had to discontinue veniafaxine, amitrazapine 45 mg/day without sedation occurring. Authors' conclu- sion: CNS Spectr 2006;11:757- 60. 9 65 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with mirtazapine. Mitrazapine trough concentrations were measured on a weekly basis after attaining steady state. 20% of relevant co- medication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients with co-medication was too small to investigate the relevance of the effect on mirtazapine clearance. A multiple linear regression analysis did not identify the CYP2C19 genotype as o possible relevance of mirtazapine clearance Addition of the CYP2C19 genotype to a population pharmacokinetic model for mirtazapine clearance of mirtazapine addition of the CYP2C19 genotype to a population pharmacokinetic model for mirtazapine clearance did not improve the prediction of plasma concentrations. NOTE: only the predominant null allele *2 was genolyped. CYP2C19 geno- type and co-me- i			(percentual reduction in				
PM: AA Im: AB			HAMD ₂₁ score)	(There was a trend for an associa-			
IM: AA % of patients with remission NS dose-corrected concentra- tion of mitazapine NS vote: Genotyping was for *2 and *17. These are the most important gene variants in this German population. Authors' conclu- sion: ref. 2 1 A 50-year-old woman who previously had to discontinue venlafaxine, amitriptyline and escitalopram monotherapies due to side effects was found to be CYP2C19 *2/*2 and CYP2D6 *4/*4. She was started on mitrazapine 45 mg/day without sedation occurring. Authors' conclu- sion: 2D6 and 2C19: a case report on antidepres- sant treatment. CNS Spectr 2006;11:57- 60. S 65 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with mitrazapine. Mitrazapine trough concentrations were measured on a weekly basis after attaining steady state. 20% of the trough concentrations measured were found in users of relevant co- medication (16% CYP2C19 substrates and 4% CYP2C19 initiotry). The number of patients with co-medication was too small to investigate the relevance of the effect on mitrazapine clearance. A multiple linear regression analysis did not identify the CYP2C19 genotype as a possible relevant factor in the clearance of mitrazapine clearance of mitrazapine clearance did not improve the prediction of plasma concentrations. NOTE: only the predominant null allele *2 was genotyped. The following covariates were included in the clearance mixed- effects specifica- tion to model				tion before Bonferroni-correction (p = 0.059 NS))			
ref. 2 Johnson M et al. 1 A 50-year-old woman who previously had to discontinue venlafaxine, amitriptyline and escitalopram monotherapies due to side effects was found to be CYP2C19 *2/² and CYP2D6 *4/*4. She was started on mirtazapine 45 mg/day without sedation occurring. A uthors' conclu- sion: "The patient azapine 45 mg/day without sedation occurring. PM: AA a case report on antidepres- sant treatment. CNS Spectr 2006;11:757- 60. B 65 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with miritazapine. Miritazapine trough concentrations were medication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients with co-medication was too small to investigate the relevance of the effect on miritazapine clearance. A multiple inear regression analysis did not identify the CYP2C19 inhibitors). The number of patients with co-medication was too small to investigate the relevance of the effect on miritazapine clearance. A multiple inear regression analysis did not identify the CYP2C19 inhibitors). The number of patients with co-medication or parameckinetic model for miritazapine. Clearance of initazapine clearance of miritazapine A multiple inear regression analysis did not identify the CYP2C19 inhibitors). The number of patients with co-medication markace clearance of plasma concentrations. Authors' conclu- sion: "The clearance of the clearance of these patients." The following covariates were included in the clearance mixed- effects specifica- ntly influenced the clearance of these patients." The following covariates were included in the clearance of the cle		UM: AA	% of patients with remission	NS			
Item of mirtazapine Authors' conclusion: ref. 2 1 A 50-year-old woman who previously had to discontinue venlafaxine, amitriptyline and escitalopram monotherapies due to side effects was found to be CYP2C19 *2/*2 and CYP2D6 *4/*4. She was started on mirtazapine 45 mg/day without sedation occurring. Authors' conclusion: The patient seemed to respond well to mirtazapine 45 mg/day without sedation occurring. Authors' conclusion: The patient seemed to respond well to mirtazapine 45 mg/day without sedation occurring. Authors' conclusion: The patient seemed to respond well to mirtazapine 45 mg/day without sedation occurring. The patient seemed to respond well to mirtazapine 40 mg/day without sedation occurring. Authors' conclusion: "The patient seemed to respond well to mirtazapine for its metabolism." 206 and 2C19: a case report on anticipres- 3 65 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with mirtazapine. Mirtazapine Chorentrations were treated with mirtazapine. Mirtazapine chorentrations were found in users of relevant comedication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients with co-medication was too small to investigate the relevance of the terarance. A multiple linear regression analysis did not identify the CYP2C19 genotype as a possible relevant factor in the clearance of mirtazapine. An ultiple linear regression analysis did not improve the prediction of plasma concentrations. NOTE: only the predominant null allele *2 was genotyped. Nother factor significa nthy influenced the clearance mixed effects specifica- ntiving invidual variability: CYP2C19 genotype and co-me- included in the clearance of thesespatients."			dose-corrected concentra-	NS			
ref. 2 Note: Genotyping was for *2 and *17. These are the most important gene variants in this German population. Authors' conclusion: The patient was found to discontinue veniafaxine, amitriptypine and excitalopram monotherapies due to side effects was found to be CYP2C19 *2/*2 and CYP2D6 *4/*4. She was started on mintazapine 45 mg/day without sedation occurring. Authors' conclusion: "The patient seemed to respondent to a searce of the cype of CYP2C19 *2/*2 and CYP2D6 *4/*4. She was started on mintazapine, a drug that does not depend extensively on CYP 2D6 or CYP 2D06 intermeasured on a weekly basis after attaining steady state. 20% of the trough concentrations measured were found in users of relevant co. The number of patients with co-medication was to small to mintazapine. Authors' conclusion: "The clearance of CYP2C19 inhibitors). The number of patients with co-medication was too small to mintazapine. Authors' conclusion: "The clearance of the CYP2C19 genotype to a population pharmacokinetic analysis of mintazapine clearance of the effect on mintazapine. Authors' conclusion: "The clearance of the CYP2C19 genotype as a possible relevant factor in the clearance of mintazapine. Addition of the CYP2C19 genotype to a population pharmacokinetic Addition of the CYP2C19 genotype as a possible relevant factor in the clearance of these patients." "The following covariates were included in the clearance of these patients." "The following covariates were included in the clearance of these patients." "The following covariates were included in the clearance of the clearance of these patients." "The following covariates were included in the clearance of these patients." "The following covariates were included in the clearance of these patients." "The following covariates were included in the clearance of these patients." "The following covariates were included in the clearance of these patients." "The following covariates were included in the cleara			tion of mirtazapine				
Note: Genoryping was for "2 and "1". These are the most important gene variants in this German population.Authors' conclu- sion: "The patient seemed to res- pond well to mir- tazapine. At the CYP2C19".Authors' conclu- sion: "The patient seemed to res- pond well to mir- tazapine, a drug tat does not depend exten- sively on CYP 206;11:757- 60.Authors' conclu- sion: "The patient seemed to res- pond well to mir- tazapine, a drug 206 and 2C19: a case report con antidepres- sant treatment. CNS Spectr 2006;11:757- 60.Spectr a concentrations measured were found in users of relevant co- medication (16% CYP2C19 and the clearance of trough concentrations measured were found in users of relevant co- medication (16% CYP2C19 genotype to a population pharmacokinetic model for mirtazapine clearance of the effect on mirtazapine clearance. A multiple linear regression analysis did not identify the CYP2C19 genotype as a possible relevant factor in the clearance of model for mirtazapine clearance of mirtazapine clearance of model for mirtazapine clearance did not improve the prediction of plasma concentrations.Authors' conclu- sion: "The clearance of CYP2D6 inter- mediate metabo- lisers. No other factor significa ntly influenced the clearance of model for mirtazapine clearance did not improve the prediction of plasma concentrations.Authors' conclu- sion: "The following covariates were included in the clearance mixed- effects specifica- ton to model interindividual variable.0.IM: AAIM: AAIM: AAMitter clearance did not improve the prediction of plasma concentrations.Mitter clearance of the sepatients." "The following covariates were included in the cleara			Note: Orantaria a use for to a				
ref. 2 Johnson M et al.1A 50-year-old woman who previously had to discontinue venlafaxine, amitriptyline and escitalopram monotherapies due to side effects was found to be CYP2C19 *2/*2 and CYP2D6 *4/*4. She was started on mitrazapine. 45 mg/day without sedation occurring.Authors' conclu- semed to res- pond well to mir- tazpine, a drug that does not depend exten- source treated with mirtazapine. 45 mg/day without sedation occurring.Authors' conclu- semed to res- pond well to mir- tazpine, a drug that does not depend exten- source treated with mirtazapine.Authors' conclu- semed to res- pond well to mir- tazpine, a drug that does not depend exten- source treated with mirtazapine.Authors' conclu- semed to res- pond well to mir- tazpine, a drug that does not depend exten- source treated with mirtazapine.Authors' conclu- sine treated with mirtazapine.For 5.3 CONS Spectr 2006;11:757- 60.365 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with mirtazapine. Mirtazapine trough concentrations were measured on a weekly basis after attaining steady state. 20% of the trough concentrations measured were found in users of relevant co- medication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients with co-medication was too small to investigate the relevance of the effect on mirtazapine. Addition of the CYP2C19 genotype to a population pharmacokinetic model for mirtazapine clearance did not improve the prediction of plasma concentrations. NOTE: only the predominant null allele *2 was genotyped.Authors' conclu- sine disents." The following covariates were included in the clearance of the clearance of the clearance of the specification with sub- treates speci			Note: Genotyping was for "2 and gene variants in this German by	a "17. These are the most important			
Johnson M et al. A poor metabo- lizer for cyto- chromes P450 2D6 and 2C19: a case report on antidepres- sant treatment. CNS Spectr 2006;11:757- 60. ref. 3 Grasmäder K et al. Population pharmacokine- tic analysis of mirtazapine. Eur J Clin Phar- macol 2004;60:473- 80. M: AA M: AA	ref. 2	1	A 50-vear-old woman who prev	viously had to discontinue venlafaxine.	Authors' conclu-		
al. A poor metabo- lizer for cyto- chromes P450 2D6 and 2C19: a case report on antidepres- sant treatment. CNS Spectr 2006;11:757- 60. ref. 3 G5 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with mirtazapine. Mirtazapine for adher attaining steady state. 20% of the trough concentrations measured were found in users of relevant co- medication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients with co-medication was too small to investigate the relevance of the effect on mirtazapine clearance. A multiple linear regression analysis did not identify the CYP2C19 inhibitors). NOTE: only the predominant null allele *2 was genotyped. NOTE: only the predominant null allele *2 was genotyped. CYP2C19 geno- type and co-me- dication with sub- comparison. CYP2C19 geno- type and co-me- dication with sub-	Johnson M et	-	amitriptyline and escitalopram	monotherapies due to side effects was	sion:		
A poor metado- lizer for cyto- chromes P450 2D6 and 2C19: a case report on antidepres- sant treatment. CNS Spectr 2006;11:757- 60.PM: AAmirtazapine 45 mg/day without sedation occurring.Seemed to res- pond well to mir- tazapine, a drug that does not depend exten- sively on CYP 2D6 or CYP <	al.		found to be CYP2C19 *2/*2 and	d CYP2D6 *4/*4. She was started on	"The patient		
 Inclusion of the second second	A poor metabo-	PM: AA	mirtazapine 45 mg/day without	sedation occurring.	seemed to res-		
2D6 and 2C19: a case report that does not depend exten-sively on CYP 2D6 and 2C19: a case report treatament. CNS Spectr 2006;11:757-60. 206 or CYP 2006;11:757-60. a case are accord on a weekly basis after attaining steady state. 20% of the trough concentrations were measured on a weekly basis after attaining steady state. 20% of the trough concentrations measured on a weekly basis after attaining steady state. 20% of the trough concentrations measured were found in users of relevant comedication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients with co-medication was too small to investigate the relevance of the effect on mitrazapine. Authors' conclusion: "The clearance of CYP2D6 intermediate metabolisers." The clearance of mitrazapine dearance did not identify the CYP2C19 genotype as a possible relevant factor in the clearance of mitrazapine. Compared with normal metabolisers. No other factor significa ntly influenced the clearance of the sepatients." "The following covariates were included in the clearance of the sep atients." "The following covariates were included in the clearance mixed-effects specification to model interindividual variability: CYP2C19 genotype and co-medication with sub-specification to model interindividual variability: CYP2C19 genotype and co-medication with sub-specification the clearance mixed-effects specification to model interindividual variability: CYP2C19 genotype and co-medication with sub-specification the clearance context and compared with the clearance context and the cle	chromes P450				tazapine, a drug		
a case report on antidepres- sant treatment. CNS Spectr 2006;11:757- 60. ref. 3 3 Grasmäder K et al. Population pharmacokine- tic analysis of mirtazapine. Eur J Clin Phar- macol 2004;60:473- 80. M: AA IM: AA	2D6 and 2C19:				that does not		
on anudepressent treatment. Sively on CYP CNS Spectr 2006;11:757-60. 60. ff. 3 ref. 3 65 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with mirtazapine. Mirtazapine trough concentrations were measured on a weekly basis after attaining steady state. 20% of the trough concentrations measured were found in users of relevant comedication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients with co-medication was too small to investigate the relevance of the effect on mirtazapine clearance. A multiple linear regression analysis did not identify the CYP2C19 genotype as a possible relevant factor in the clearance of mirtazapine. Addition of the CYP2C19 genotype to a population pharmacokinetic model for mirtazapine clearance did not improve the prediction of plasma concentrations. NOTE: only the predominant null allele *2 was genotyped. Wetweet were included in the clearance of the effects specification to model interindividual variability: CYP2C19 genotype and co-mective and the clearance of the separates.	a case report				depend exten-		
CNS Spectr 2006;11:757- 60. ref. 3 al. Population pharmacokine- tic analysis of mirtazapine. Eur J Clin Phar- macol 2004;60:473- 80. IM: AA IM: A	on antidepres-				2D6 or CYP		
2006;11:757- 60. metabolism." form 3 form 65 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were treated with mirtazapine. Mirtazapine trough concentrations were measured on a weekly basis after attaining steady state. 20% of the trough concentrations measured were found in users of relevant co- medication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients with co-medication was too small to investigate the relevance of the effect on mirtazapine clearance. A multiple linear regression analysis did not identify the CYP2C19 genotype as a possible relevant factor in the clearance of mirtazapine. Addition of the CYP2C19 genotype to a population pharmacokinetic model for mirtazapine clearance did not improve the prediction of plasma concentrations. NOTE: only the predominant null allele *2 was genotyped. "The following covariates were included in the clearance mixed- effects specifica- tion to model interindividual variability: CYP2C19 geno- type and co-me- dication with sub-	CNS Spectr				2C19 for its		
 60. ref. 3 G5 patients, including 49 genotyped (39x *1/*1, 10x *1/*2), were Grasmåder K et al. Population pharmacokine-tic analysis of mirtazapine. Eur J Clin Pharmacol 2004;60:473-80. IM: AA IM: AA	2006;11:757-				metabolism."		
 Grasmäder K et al. Population pharmacokine- tic analysis of mitazapine. Eur J Clin Pharmacol 2004;60:473- 80. IM: AA IM: AA<th>60.</th><th>2</th><th>65 potients including 40 genet</th><th>(nod (20) *1/*1 10) *1/*2) ware</th><th>Authora' conclu</th>	60.	2	65 potients including 40 genet	(nod (20) *1/*1 10) *1/*2) ware	Authora' conclu		
al. Population pharmacokine- tic analysis of mirtazapine. Eur J Clin Phar- macol 2004;60:473- 80. IM: AA IM: AA IM: AA IM: AA	Grasmäder K et	3	treated with mirtazapine Mirtaz	rapine trough concentrations were	sion:		
Population pharmacokine- tic analysis of mirtazapine. Eur J Clin Phar- macol 2004;60:473- 80.trough concentrations measured were found in users of relevant co- medication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients with co-medication was too small to investigate the relevance of the effect on mirtazapine clearance. A multiple linear regression analysis did not identify the CYP2C19 genotype as a possible relevant factor in the clearance of mirtazapine. Addition of the CYP2C19 genotype to a population pharmacokinetic model for mirtazapine clearance did not improve the prediction of plasma concentrations.CYP2D6 inter- mediate metabo- lisers was redu- ced by 26% compared with normal metabo- lisers. No other factor significa mity influenced the clearance of the se patients." "The following covariates were included in the clearance mixed- effects specifica- tion to model interindividual variability: CYP2C19 geno- type and co-me- dication with sub-	al.		measured on a weekly basis af	ter attaining steady state. 20% of the	"The clearance of		
pharmacokine- tic analysis of mirtazapine.medication (16% CYP2C19 substrates and 4% CYP2C19 inhibitors). The number of patients with co-medication was too small to investigate the relevance of the effect on mirtazapine clearance. A multiple linear regression analysis did not identify the CYP2C19 genotype as a possible relevant factor in the clearance of mirtazapine. Addition of the CYP2C19 genotype to a population pharmacokinetic model for mirtazapine clearance did not improve the prediction of plasma concentrations.mediate metabo- lisers was redu- ced by 26% compared with normal metabo- lisers. No other factor significa ntly influenced the clearance of the clearance of these patients." "The following covariates were included in the clearance mixed- effects specifica- tion to model interindividual variability: CYP2C19 geno- type and co-me- dication with sub-	Population		trough concentrations measure	d were found in users of relevant co-	CYP2D6 inter-		
 In the number of patients with co-medication was too small to investigate the relevance of the effect on mirtazapine clearance. A multiple linear regression analysis did not identify the CYP2C19 genotype as a possible relevant factor in the clearance of mirtazapine. Addition of the CYP2C19 genotype to a population pharmacokinetic model for mirtazapine clearance did not improve the prediction of plasma concentrations. IM: AA IM: AA<	pharmacokine-		medication (16% CYP2C19 sul	ostrates and 4% CYP2C19 inhibitors).	mediate metabo-		
Eur J Clin Phar- macol 2004;60:473- 80. IM: AA IM:	mirtazapine.		I he number of patients with co	-medication was too small to	ced by 26%		
macol 2004;60:473- 80.genotype as a possible relevant factor in the clearance of mirtazapine. Addition of the CYP2C19 genotype to a population pharmacokinetic model for mirtazapine clearance did not improve the prediction of plasma concentrations.normal metabo- lisers. No other factor significa ntly influenced the clearance of these patients." "The following covariates were included in the clearance mixed- effects specifica- tion to model interindividual variability:	Eur J Clin Phar-		A multiple linear regression and	alvsis did not identify the CYP2C19	compared with		
Addition of the CYP2C19 genotype to a population pharmacokinetic model for mirtazapine clearance did not improve the prediction of plasma concentrations. NOTE: only the predominant null allele *2 was genotyped. INCTE: only the predominant null allele *2 was genotyped.	macol		genotype as a possible relevan	normal metabo-			
IM: AA IM: AA IM	2004;60:473-		Addition of the CYP2C19 genor	type to a population pharmacokinetic	factor significa		
IM: AA plasma concentrations. NOTE: only the predominant null allele *2 was genotyped. **The following covariates were included in the clearance mixed- effects specifica- tion to model interindividual variability: CYP2C19 geno- type and co-me- dication with sub-	00.	184. 6.6	model for mirtazapine clearanc	e did not improve the prediction of	ntly influenced		
NOTE: only the predominant null allele *2 was genotyped. "The following covariates were included in the clearance mixed- effects specifica- tion to model interindividual variability: CYP2C19 geno- type and co-me- dication with sub-		INI: AA	plasma concentrations.		the clearance of		
covariates were included in the clearance mixed- effects specifica- tion to model interindividual variability: CYP2C19 geno- type and co-me- dication with sub-			NOTE: only the predominant nu	ull allele *2 was genotyped.	these patients."		
included in the clearance mixed- effects specifica- tion to model interindividual variability: CYP2C19 geno- type and co-me- dication with sub-				0 11	covariates were		
clearance mixed- effects specifica- tion to model interindividual variability: CYP2C19 geno- type and co-me- dication with sub-					included in the		
effects specifica- tion to model interindividual variability: CYP2C19 geno- type and co-me- dication with sub-					clearance mixed-		
interindividual variability: CYP2C19 geno- type and co-me- dication with sub-					effects specifica-		
variability: CYP2C19 geno- type and co-me- dication with sub-					interindividual		
CYP2C19 geno- type and co-me- dication with sub-					variability:		
type and co-me-					CYP2C19 geno-		
					type and co-me-		

ref. 3, continu- ation	strates of CYP- 2C19"
ation	2C19"

Risk group

Comments:

- The article of Zastrozhin 2021 (Zastrozhin MS et al. Impact of the omics-based biomarkers on the mirtazapine's steady-state concentration, efficacy and safety in patients with affective disorders comorbid with alcohol use disorder. Psychopharmacol Bull 2021;51:31-42. PMID: 34092821) was not included in the risk analysis, because it was unclear whether the right data were reported. The article reported that no patient was found to be *2/*2 or *3/*3, but did report outcome data for these genotypes. In addition, the table with outcome data only contains a heading Concentration of fluvoxamine, but not a heading Concentration of mirtazapine. Finally, the article indicated the alleles with the highest frequency to be the minor alleles instead of the major alleles and reported a mean dose of 45 mg/week, which is an unlikely dosing schedule for mirtazapine.
- Possible relationship between CYP2C19 polymorphisms and depression:

- Jukić MM et al. Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment. Mol Psychiatry 2017;22:1155-1163. PubMed PMID: 27895323. This publication is from the same group as Sim 2010.

In a cohort of 3849 urban African-Americans of low economic status, the 123 CYP2C19*2/*2 subjects had a decrease in major depressive disorder prevalence compared to the other subjects with at least one active CYP-2C19 allele (23% versus 32%) (S). In addition, there was a trend for a lower Beck's Depression Inventory (BDI) score in the CYP2C19*2/*2 subjects compared to the other subjects (p = 0.074). However, the lifetime stress exposure was much larger in the African-American cohort compared with the previously analysed Swedish cohort (Sim 2010), thereby increasing the BDI score variability. After the most traumatized subjects (perceived stress scale score at higher quartile and above) were exempted from the analysis to better match the two samples, the BDI score reduction was significant (effect size = - 2.05 (-24.61%)) (S).

In order to test whether the CYP2C19 genotype influences suicidality in patients with major depressive disorder, CYP2C19 genotype was tested as a predictor for suicide intent in 209 Western European suicide attempters with major depressive disorder. As there were only two CYP2C19*2/*2 allele carriers in the cohort, it was not possible to test whether this genotype affects Beck's suicide intent scale-objective circumstances (SIS-OS) score. However, in a complementary exploratory analysis, the SIS-OS score seemed to vary between different CYP2C19 genotypes with a decrease for *2/*2 versus *1/*1 versus *1/*2 versus *2/*17 versus *17/*17 versus *1/*17. Further analysis showed that SIS-OS score was not significantly affected by the presence of the CYP2C19*2 allele, whereas it was significantly increased in CYP2C19*17 allele carriers (119 versus 90 subjects, effect size = +1.36 (+25.69%)) (S). Since the score was lower for the 8 patients with genotype *17/*17 compared to the patients with genotype *1/*17, this significant effect seemed to be mainly driven by the *1/*17 genotype. The classification of the suicide attempters to severe (SIS-OS score at higher quartile and above) and non-severe, yielded a higher frequency of patients with *17 allele among severe suicide attempters (S).

The authors conclude that the CYP2C19*2/*2 genotype associates with a phenotype more resilient to major depressive disorder and that the CYP2C19*17 allele may be a risk allele for suicidality in major depressive disorder. They indicate that a major limitation of the suicidality study is the absence of information regarding the individuals' drug treatment and their drug plasma levels. Therefore, it was not possible to determine whether the observed relationship was caused by endogenous or drug-metabolic CYP2C19-mediated effects.

- Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 2013;18:497-511. PubMed PMID: 22472876. A mega-analysis of genome-wide association studies found no significant association between the risk of depression and CYP2C19.
- Sim SC et al. Association between CYP2C19 polymorphism and depressive symptoms. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:1160-6.

In a group of 1472 Europeans older than 44 years (1017x NM (637x *1/*1, 380x *1/*17), 375x IM (290x *1/*2, 85x *2/*17), 35x PM (*2/*2), 45x UM), significantly lower depressive symptoms (measured on the Center of Epidemiologic Studies Depression (CES-D) scale) were found among PM patients than among *1/*1. There was only a difference among people younger than 73 years and among men. The effect size was in the same order of magnitude as that observed between non-users and users of antidepressants. The authors stated that CYP2C19 poly-morphisms may have an effect on depressive symptoms in adult Europeans.

Date of literature search: 19 September 2022.

Phenotype Code Gene-drug interaction Action Date

KNMP Pharmacogenetics	PM	3 AA	no	no	14 November 2022
Working Group decision	IM	3 AA	no	no	
	UM	3 AA	no	no	

Mechanism:

Mirtazapine is converted by CYP2D6 and CYP1A2 to inactive hydroxy metabolites. Mirtazapine is also converted by CYP3A4 to the pharmacologically active N-demethyl metabolite and inactive N-oxide metabolites.